We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Blood Group Locus Contributes to COVID-19 Severity Risk

By LabMedica International staff writers
Posted on 02 Jul 2020
There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). More...


Severe COVID-19 with respiratory failure requires early and prolonged support by mechanical ventilation. Clinical associations have also been reported for hypertension, diabetes, and other obesity-related and cardiovascular disease traits, but the relative role of clinical risk factors in determining the severity of COVID-19 has not yet been clarified.

An international team of scientists led by the Kiel University (Kiel, Germany) conducted a genome-wide association study and meta-analysis encompassing thousands of COVID-19 patients treated at hospitals in Italy, Spain, Norway, and Germany. These included 1,980 individuals with PCR-confirmed SARS-CoV-2 infections who experienced respiratory failure as well as seemingly healthy control individuals from the same populations.

The scientists performed DNA extraction using a Chemagic 360 (PerkinElmer, Waltham, MA, USA) with the use of the low-volume kit CMG-1491 and the buffy-coat kit CMG-714 (Chemagen, Baesweiler, Germany), respectively. For genotyping, they used the Global Screening Array (GSA), version 2.0 (Illumina, San Diego, CA, USA), which contains 712,189 variants before quality control. The analyses used array-based genotyping profiles based on nearly 8.6 million single nucleotide polymorphisms (SNPs).

The investigators detected cross-replicating associations with rs11385942 at locus 3p21.31 and with rs657152 at locus 9q34.2, which were significant at the genomewide level. At locus 3p21.31, the association signal spanned six genes. The association signal at locus 9q34.2 coincided with the ABO blood group locus; in this cohort, a blood-group–specific analysis showed a higher risk in blood group A than in other blood groups (odds ratio, 1.45) and a protective effect in blood group O as compared with other blood groups.

The team explained that non-genetic studies that were reported as preprints have previously implicated the involvement of ABO blood groups in COVID-19 susceptibility, and ABO blood groups have also been implicated in susceptibility to SARS-CoV-1 infection. Their genetic data confirm that blood group O is associated with a risk of acquiring COVID-19 that was lower than that in non-O blood groups, whereas blood group A was associated with a higher risk than non-A blood groups.

The authors concluded that they had identified a 3p21.31 gene cluster as a genetic susceptibility locus in patients with COVID-19 with respiratory failure and confirmed a potential involvement of the ABO blood-group system. The study was published on June 17, 2020 in The New England Journal of Medicine.



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Droplet Digital PCR System
QX600 AutoDG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.